UBS Raises Equifax (NYSE: EFX) Price Target to $215, Reaffirms Buy

UBS analyst Kevin Mcveigh raised his price target on Equifax (NYSE: EFX) to $215 from $212 on Wednesday, reaffirming a Buy rating even as the stock fell 7.35% to close at $154.84. The revised target lands well above the current share price, which touched $153.91 intraday, near the lower bound of its 52-week range of $153.91 to $275.91.

What Changed

• New price target: UBS raised its EFX target to $215 from $212, a $3 increase, with the Buy rating unchanged.
• Analyst: Kevin Mcveigh of UBS issued the revised target on Wednesday, June 17, 2026.
• Session move: EFX fell 7.35% on Wednesday, closing at $154.84 against a previous close of $167.13.
• Broad consensus: Wall Street's current consensus stands at 8 Strong Buy, 12 Buy, and 10 Hold ratings, with zero Sell or Strong Sell calls as of June 1, 2026.

Why It Matters

The UBS target raise arrives on the same session that Equifax shares came under pressure, with reporting from Quiver Quantitative citing investor refocus on the company's rate-sensitive mortgage business and regulatory headline risk. Separately, GuruFocus reported that U.S. senators have challenged Equifax on student loan reporting practices, adding a regulatory dimension to the stock's near-term narrative.

Despite those pressures, UBS's decision to lift its price target signals continued conviction in the company's outlook. The $215 target implies meaningful upside from Wednesday's close of $154.84, and the unchanged Buy rating keeps UBS aligned with a Wall Street consensus that carries no Sell or Strong Sell ratings across its 30 active recommendations.

Wall Street View

UBS's revised $215 target sits alongside a consensus of 20 Buy-or-better recommendations versus 10 Hold ratings as of June 1, 2026. The $3 target increase from UBS is modest, but the timing, issued on a day of sharp selling, underscores the firm's view that Wednesday's move does not alter the fundamental investment case for Equifax.

Investor Takeaway

UBS's price target increase to $215, maintained on a day EFX fell 7.35% to $154.84, reflects analyst confidence that near-term regulatory and mortgage-market pressures do not structurally impair the long-term thesis. With the share price now trading significantly below the revised target and Wall Street carrying zero Sell ratings, the gap between current price and analyst expectations is the defining question for investors following this name.